Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans

This is a single-arm, open-label study to assess the safety and effectiveness of a single dose of oral propranolol in reducing18F-fluorodeoxyglucose (FDG) uptake in brown adipose tissue (BAT) in pediatric oncology patients. This study is designed to better understand if taking a single dose of an oral medication called propranolol can reduce the chance of brown fat showing up on a PET scan, and therefore make the scan more accurate and easy to interpret. All humans have some degree of normal brown fat (called brown adipose tissue), and this normal tissue can sometimes light up on a PET scan. That creates problems because it may be wrongly interpreted by the radiologist as tumor, or it may hide true areas of tumor underneath it. Participants will not be randomized and will receive a single dose of oral propranolol approximately 60 minutes prior to the injection of the FDG tracer. The dose of propranolol will be 20 mg for all participants.

Sex

All

Minimum age

12 Years

Maximum age

29 Years

Inclusion Criteria:

* Individual is between 12 years and 29 years of age
* Individual weighs over 66 pounds
* Individual will be undergoing a FDG-PET scan as part of staging or response assessment for malignancy. Note: the patient may be newly-diagnosed, currently receiving therapy, or have already completed therapy. The presence of identifiable tumor on the PET scan is not required.
* Individual is able to swallow a tablet

Exclusion Criteria:

* Prior diagnosis of asthma, OR use of an inhaler in past three years to treat or prevent bronchospasm.
* History of cardiac arrhythmia requiring treatment
* History of congestive heart failure
* Current use of medications to control blood pressure or improve cardiac output
* Diabetes Type I or II, or currently on medications to reduce blood sugar
* Pregnant